Vascular endothelial growth factor and basic fibroblast growth factor evaluation in blood serum of patients with hormonally active and inactive adrenal gland tumours

Cytobios

Volumn 2000, Issue 396, 2000, Pages 55-64

  Kolomecki K ^a   Stepien H ^a   Narebski J M ^a  

^a MEDICAL UNIVERSITY OF LODZ   (Poland)

Author keywords

Adrenal tumour; Angiogenesis; bFGF; VEGF

Indexed keywords

ENDOTHELIAL CELL GROWTH FACTOR; FIBROBLAST GROWTH FACTOR; LYMPHOKINE; PRASTERONE; VASCULOTROPIN; VASCULOTROPIN A;

ADRENAL CORTEX TUMOR; ADRENAL MEDULLA; ADRENAL TUMOR; ADRENALECTOMY; ADULT; AGED; ARTICLE; BLOOD; CARCINOMA; CHEMISTRY; CUSHING SYNDROME; FEMALE; HUMAN; HYPERALDOSTERONISM; MALE; MIDDLE AGED; PHEOCHROMOCYTOMA;

ADRENAL CORTEX NEOPLASMS; ADRENAL GLAND NEOPLASMS; ADRENAL MEDULLA; ADRENALECTOMY; ADULT; AGED; CARCINOMA; CUSHING SYNDROME; DEHYDROEPIANDROSTERONE; ENDOTHELIAL GROWTH FACTORS; FEMALE; FIBROBLAST GROWTH FACTORS; HUMANS; HYPERALDOSTERONISM; LYMPHOKINES; MALE; MIDDLE AGED; PHEOCHROMOCYTOMA; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTORS;

EID: 0033629896     PISSN: 00114529     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (36)

1. ASAHARA T., Bauters C., Zheng L P., Takeshita S., Bunting S., Ferrara N., Symes J .F. and Isner J. M. 1995. Synergistic effect of vascular endothelial growth factor and basic fibroblast factor on angiogenesis in vivo. Circulation 92 365-71.
2. AUERBACH W. and Auerbach R. 1994. Angiogenesis inhibition: a review. Pharmacol. Ther. 63 265-311.
3. BORDI C., Folchetti A., Buffa R., Azzoni C., D'Adda T., Caruana P., Rindi G. and Brandi L. M. 1994. Production of basic fibroblast factor by gastric carcinoid tumors and their putative cells origin. Am. J. Path. 25 175-80.
4. +2 and von Willebrand factor release in human endothelial cells. Am. J. Path. 138 213-21.
5. BROWN L. F., Berse B., Jackman R. W., Tognazzi K., Mansean E. J., Dvorak H. F. and Senger D. R. 1993a. Increased expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in kidney and bladder carcinoma. Am. J. Path. 143 1255-62.
6. BROWN L. F., Berse B., Jackman R. W., Tognazzi K., Mansean E. J., Senger D. R. and Dvorak H. F. 1993b. Expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in adenocarcinomas of the gastrointestinal tract. Cancer Res. 53 4727-35.
7. BROWN L F., Berse B. and Jackman R. W. 1995. Expression of vascular permeability factor (VEGF) and its receptors in breast cancer. Hum. Path. 26 86-91.
8. BUSSOLINO F., Albini A., Carnussi G., Presta M., Viglietto G., Ziche M. and Persico G. 1996. Role of soluble mediators in angiogenesis. Eur. J. Cancer 14 2401-12.
9. CAMPBELL S. C. 1997. Advances in angiogenesis research: revelance to urological oncology. J. Urol. 158 1663-74.
10. CONTRINO J., Hair G. and Kreutzer D. L. 1996. In situ detection of tissue factor in vascular endothelial cells: correlation with the malignant phenotype of human breast cancer. Nature Med. 2 209-15.
11. DAITCH J. A., Goldfarb D. A. and Novick A. C. 1997. Cleveland Clinic experience with adrenal Cushing's syndrome. J. Urol. 158 2051-5.
12. DVORAK H. F. 1986. Tumors: wounds that do not heal. New Engl. J. Med. 315 1650-9.
13. FERRARA N., Houck K., Jakeman L. and Leung D. W. 1992 Molecular and biological properties of the vascular endothelial growth factor family of proteins. Endocrine Rev. 13 18-32.
14. FIDLER I. J. and Ellis L. M. 1994. The implications of angiogenesis to the biology and therapy of cancer metastasis. Cell 79 185-8.
15. FOLKMAN J. 1990. What is the evidence that tumors are angiogenesis dependent? J. natn. Cancer Inst. 82 4-6.
16. FOLKMAN J., Szabo S., Stavroff M., McNeil P., Li W. and Shing Y. 1991. Duodenal ulcer. Discovery of a new mechanism and development of angiogenic therapy that accelerates healing. Ann. Surg. 214 414-27.
17. FOLKMAN J. 1995. Angiogenesis in cancer, vascular rheumatoid and other disease. Nature Med. 1 27-31.
18. FOLKMAN J., Watson K., Ingberg D. and Hanahan D. 1989. Induction of angiogenesis during the transition from hyperplasia to neoplasia. Nature 339 58-61.
19. FUJIMOTO K., Ichimori Y. and Yamaguchi H. 1995. Basic fibroblast growth factor as a candidate tumor marker for renal cell carcinoma. Jpn. J. Cancer Res. 86 182-6.
20. GABRILOVE J. L., Freiberg E. K. and Nicolis G. L. 1983. Peripheral blood steroid levels in Cushing syndrome due to adrenocortical carcinoma or adenoma. Urology 22 576-82.
21. GASPARINI G. and Harris A. L. 1995. Clinical importance of the determination of tumor angiogenesis in breast carcinoma: much more than a new prognostic tool. J. clin. Oncol. 3 765-82.
22. GOSPODAROWICZ D. 1989. The fibroblast growth factor. Oncogenesis 1 1-25.
23. KIM K.J., Li B., Viner J., Armanini M., Gillett N., Philips H. S. and Ferrara N. 1993. Inhibitor of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo. Nature 362 841-4.
24. KOŁOMECKI K., Pomorski L, Kuzdak K., Narȩbski J. M. and Wichman R. 1999. The surgical treatment of adrenal gland tumors - incidentalloma. Neoplasma 2 131-4.
25. KRAFT A., Weindel K., Ochs A., Marth C., Zmija J., Schumacher P., Unger C., Marme D. and Gasti G. 1999. Vascular endothelial growth factor in the sera and effusions of patients with malignant and nonmalignant disease. Cancer 1 178-87.
26. MAEDA K., Chung Y. S. and Ogawa Y. 1996. Prognostic value of vascular endothelial growth factor expression in gastric carcinoma. Cancer 77 858-63.
27. MATTERN J., Koomagi R. and Voom M. 1996. Association of vascular endothelial growth factor expression with intratumoral microvessel density and tumour cell proliferation in human epidermoid lung carcinoma. Br. J. Cancer 73 931-4.
28. SATO K., Yamazaki K. and Shizume K. 1995. Stimulation by thyroid-stimulating hormone and Grave's immunoglobulin G of vascular endothelial growth factor mRNA expression in the rat thyroid in vivo. J. clin. Invest. 96 1295-302.
29. TAKAHASHI Y., Kitadai Y., Bucana C. D., Cleary K. R. and Ellis L. M. 1995. Expression of vascular endothelial growth factor and its receptor, KDR, correlates with vascularity, metastasis and proliferation of human colon cancer. Cancer Res. 55 3964-8.
30. TOI M. 1995. Endothelial growth factors: a target for antiangiogenesis. Cancer J. 8 315-9.
31. TOI M., Hoshima S., Takayanagi T. and Tominaga T. 1994. Association of vascular endothelial growth factor expression with tumor angiogenesis and with early relapse in primary breast cancer. Jpn. J. Cancer 85 1045-9.
32. TOI M., Inada K., Suzuki H. and Tominaga T. 1995. Tumor angiogenesis in breast cancer: its importance as a prognostic indicator and the association with vascular endothelial growth factor expressed. Breast Cancer Res. Treat. 36 193-204.
33. TOI M., Kondo S. and Suzuki H. 1996a. Quantitative analysis of vascular endothelial growth factor in primary breast cancer. Cancer 77 1101-6.
34. TOI M., Taniguchi T., Yamamoto Y, Kurisaki T., Suzuki H. and Tominaga T. 1996b. Clinical significance of the determination of angiogenic factors. Eur. J. Cancer 14 2513-9.
35. VIGLIETTO G., Maglione D. and Rambald M. 1995. Upregulation of vascular endothelial growth factor (VEGF) and downregulation of placenta growth factor (PLGF) associated with malignancy in human thyroid tumors and cell lines. Oncogene 11 1569-79.
36. YAMAMOTO Y, Toi M. and Kondo S. 1996. Concentrations of vascular endothelial growth factor in sera of normal control and cancer patients. Clin. Cancer Res. 2 821-6.